drugset / Trial / NCT02660424

A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee

NCT02660424 ↗

Phase 2 Completed 124 enrolled Vertex Pharmaceuticals Incorporated
RandomizedCrossoverDouble-blindTreatment

Summary

The Primary objective of this study is to evaluate the efficacy of VX-150 in the treatment of osteoarthritis pain

Timeline

Start
2015-12
Primary completion
2016-08
Completion
2016-09

Outcome

Met primary endpoint

release “The 14-day study, which enrolled 124 people with at least moderate pain caused by osteoarthritis of the knee, met its primary endpoint” vrtx.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject VX-150 Unknown — —

Indications